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Abstract
Background: Information regarding the distribution of evidence grades in psychiatry and psychotherapy guidelines
is lacking. Based on the German evidence- and consensus- based (S3) psychiatry and psychotherapy and the
Scottish Intercollegiate Guidelines Network (SIGN) treatment guidelines, we aimed to specify how guideline
recommendations are composed and to what extent recommendations are evidence-based.
Methods: Data was collected from all published evidence- and consensus-based S3-classified psychiatry and
psychotherapy guidelines. As control conditions, data from German neurology S3-classified guidelines as well as
data from recent SIGN guidelines of mental health were extracted. Two investigators reviewed the selected
guidelines independently, extracted and analysed the numbers and levels of recommendations.
Results: On average, 45.1% of all recommendations are not based on strong scientific evidence in German
guidelines of psychiatry and psychotherapy. A related pattern can be confirmed for SIGN guidelines, where the
mean average of recommendations with lacking evidence is 33.9%. By contrast, in the German guidelines of
neurology the average of such recommendations is 16.5%. A total of 24.5% of all recommendations in the
guidelines of psychiatry and psychotherapy are classified as level A recommendations, compared to 31.6% in the
field of neurology and 31.1% in the SIGN guidelines. Related patterns were observed for B and 0 level
recommendations.
Conclusion: Guidelines should be practical tools to simplify the decision-making process based on scientific
evidence. Up to 45% of all recommendations in the investigated guidelines of psychiatry and psychotherapy are
not based on strong scientific evidence. The reasons for this high number remain unclear. Possibly, only a limited
number of studies answer clinically relevant questions. Our findings thereby question whether guidelines should
include non-evidence-based recommendations to be methodologically stringent and whether specific processes to
develop expert-opinion statements must be implemented.
Keywords: German guidelines of psychiatry and psychotherapy, SIGN guidelines, Rrecommendations, Evidence
grade, Distribution of recommendations
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Background
Evidence-based medicine aims to integrate the best research
evidence with clinical expertise and patient values [1]. In this
regard, guidelines are systematically developed tools to assist
physicians and other health-care professionals in the
decision-making process and to support the transparency of
medical decisions. Apart from summarising the current
medical evidence, guidelines are instruments to weigh the
risk-benefit ratios of diagnostic procedures and treatments.
Guidelines are also instruments of quality management of
the healthcare system and viewed to improve quality and ef-
fectiveness of clinical as well as costs of healthcare [2].
In Germany, the Association of the Scientific Medical
Societies (AWMF) started coordinating the development
of guidelines in 1995. Since 1997 guidelines are cost-free
and publicly available online [3]. In contrast to other
countries, clinical guidelines in Germany are not state-
funded. For example, in the UK the National Institute of
Clinical Excellence (NICE) orders the development of a
clinical guideline from a group of independent experts
and finances the process [4]. In Germany, the develop-
ment is only financed by the subscriptions of the pub-
lishing medical societies [3] and by the cost-free work of
the people involved. Because of the costly and time-
intensive development process of high-quality clinical
guidelines, different options for funding are currently in
discussion. The objective would be an independent and
sustainable financial support [5] to accelerate the devel-
opment process, to consider the most recent study
results and to evaluate the guidelines. Despite an import-
ant legislative initiative to improve the funding situation
[6], it is not foreseeable that there will be a fundamental
change regarding the way how guidelines are developed
in Germany.
Regardless of any financial consideration, the develop-
ment process of German guidelines follows standard
operation procedures, developed by the AWMF aiming
at providing the same level of quality across guidelines.
More than 20 years ago clinical guidelines in Germany
were not subject to standardisation, so the AWMF
started an extensive program in 1998 to improve their
quality [3]. For this purpose, the German Rating Instru-
ment for Guideline Valuation (DELBI) has been devel-
oped based on the Appraisal of the Guidelines for
Research and Evaluation instrument (AGREE, DELBI
domains 1 to 6) and was adapted for the German health-
care system (DELBI domain 7) to minimise differences
concerning quality and underlying methodology across
guidelines and to ensure inter-comparability [7]. Similar
efforts were made by the Scottish Intercollegiate Guide-
lines Network (SIGN) as summarised in the SIGN guide-
lines developer’s handbook.
In that regard, three major classifications for guide-
lines can be distinguished in Germany. Groups of
experts develop in an informal consensus (‘expert rec-
ommendations’), which results in so called S1-classified
guidelines. By comparison S2-classified guidelines need a
formal multidisciplinary consensus. Since 2004, the dif-
ferentiation between S2e-classified (‘evidence-based’)
and S2k-classified (‘consensus-based’) exists. S2k-
guidelines are not evidence-based and recommendations
are not graded, but the consensus process is standar-
dised and has to follow standard operating procedures.
For the development of S2e-guidelines, a systematic
research process and the selection and evaluation of
evidence are required. S3-classified guidelines are evi-
dence- and consensus-based and have the highest
methodological quality as well as the most expensive
development process. After a structured literature re-
search and rating of the evidence, they have to fulfil
different DELBI criteria [3]. AWMF guidelines use
either the Oxford Centre for Evidence Based Medi-
cine (OCEBM) or the SIGN grading systems and
AWMF S3-guidelines underlie a structured consensus
process which finally leads to the recommendations
(grades A, B, 0 and CCP, see Table 1). AWMF was
one of the funding organisations of the Guidelines
International network and from the international per-
spective, AWMF S3-guidelines are rooted in one of
the most elaborated development processes.
Since 1998 the total number of published medical guide-
lines in Germany has been growing continuously, but over
the last years the proportion of S1 to S3 guidelines has
changed. In 2002, 445 S1-guidelines, 121 S2-guidelines and
17 S3-guidelines were available. In 2016, 108 S3-guidelines
were available and 374 guidelines were newly registered [8].
Since 2014 the number of newly registered guidelines has
decreased, but with a continuously increasing number of
high-quality guidelines [8, 9] which might confirm that the
process of improving the quality of guidelines in general
has been successful so far.
High methodological quality is essential to guarantee
recommendations based on scientific evidence with
practical relevance and to minimise possible conflict
of interest biases. Moreover, the amount of recom-
mendations and their respective grading levels are im-
portant from the view of usability. However, the way
of how to grade evidence and to develop guidelines
differs between countries. Nonetheless, most guide-
lines use the original or the adapted version of the
Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) process [10].
Despite important efforts to harmonise and improve
the guideline development processes, guidelines do have
a relevant proportion of non-evidence-based recommen-
dations that are presumably expert opinions. In 2014
one study of the Scottish Intercollegiate Guidelines Net-
work (SIGN) (somatic disciplines and mental health)
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evaluated the 42 national guidelines with respect to the
quantity and quality of the given recommendations. The
authors observed that only 24% of all recommendations
were based on high scientific evidence (denoted as level
A recommendations). Remarkably, more than a third of
all recommendations were expert-based recommenda-
tions and more than a half of the recommendations were
based on limited scientific evidence [11]. Moreover,
these results highlight that the number of recommenda-
tions with low or absent evidence increases with the
total amount of recommendations.
The challenge to develop high-quality guidelines in
psychiatry and psychotherapy is all the greater compared
to somatic disciplines due to the implementation of
patient reported outcomes. So called “soft endpoints”,
which are composed of patient and observer reported
outcomes collected via self- or observer-rated clinical
rating scales, questionnaires, or interviews [12]. More-
over, psychiatric disorders are subject to a high complex-
ity of diagnosis, treatment, extensive involvement of
patients and relatives and outcome measurements. One
could speculate that the desire of the guideline devel-
opers to deal with this high complexity could possibly
lead to a high amount of not evidence-based recommen-
dations. To test this hypothesis, we conducted an ana-
lysis of distribution of recommendation grades in
evidence- and consensus-based German guidelines of
psychiatry and psychotherapy compared to national
guidelines of neurology and to the internationally estab-
lished SIGN guidelines.
Methods
This study focuses on all available German S3-guidelines
in psychiatry and psychotherapy in their respective most
recent versions (status July 2019). The S3-guidelines of
neurology were investigated to serve as a first control
group to allow a comparison to a medical field with an
overlap in diagnoses or treatments. The recent SIGN
guidelines of mental health (status July 2019) were inves-
tigated as second control group taking into account the
study from Baird and colleagues published in 2014 [11].
Moreover, SIGN guidelines are based on related devel-
opment procedures to German S3-guidelines in evaluat-
ing and grading evidence allowing for a direct
comparison. Indeed, there are differences between the
SIGN- and the German S3- guideline developing
process. The most important difference is the compos-
ition of the guideline developing group: the SIGN Execu-
tive discusses which specialties and professions should
be represented on the guideline development group with
the topic proposer(s). This process is advised from the
appropriate specialty subgroup(s) and SIGN Council.
SIGN guideline development groups vary in size depend-
ing on the scope of the topic under consideration, but
generally comprise between 15 and 25 members. In con-
trast, the AWMF only proposes that all relevant interest
groups should be represented, without recommendations
about the size of the developing group. The respective
medical societies are responsible for assembling the
guideline group and developing the guideline. The
AWMF provides the methodological framework for
developing the guidelines and serves as the publisher.
To identify guidelines of interest, we screened the
AWMF database, the webpages of the publishing med-
ical societies and the SIGN webpage for all guidelines
covering psychiatric or neurological disorders. Two
independent investigators (MH and LL) selected and
evaluated all AWMF S3-guidelines published by the
German Society for Psychiatry and Psychotherapy
(DGPPN) and the German association for Neurology
(DGN) and the respective SIGN guidelines. If investiga-
tors had different results, these results were discussed
with a third investigator (AH) until a final consensus-
decision was reached.
15 from 17 guidelines, published by the DGPPN were
S3-guidelines. The two excluded guidelines were
Table 1 Grade of recommendation and underlying levels of evidence (SIGN and OCEBM); following the SIGN and the OCEBM
grading system the levels of evidence are rated in four or five categories. Results of studies can be extrapolated or interpolated so
that lower levels of evidence can underlie higher grades of recommendations and conversely
Grade of
recommendation
Description Level of evidence (SIGN) Level of evidence (OCEBM)
A Strong recommendation 1++, 1+, (1-) I, (II)
B Recommendation 2++, 2+, (2-) II, III, (I)
or downgrading of 1++ / 1+ / (1-) due to
methodological considerations
0 Open recommendation 3,4 IV, V, (II, III)
or downgrading of 2++ / 2+ / (2-) due to
methodological considerations
CCP Clinical consensus (different
strengths of recommendation
possible)
No level of evidence No level of evidence
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guidelines classified as S1 and S2: the S1-guideline for
disorders of sexual preferences and the S2-guideline for
personality disorders. We included the two content re-
lated S3-guidelines “Functional body complaints” and
“Post-traumatic stress disorder”, published only by the
AWMF, resulting in a total of 17 S3-guidelines of psych-
iatry and psychotherapy. The DGN published a total of
96 guidelines with only five S3-guidelines. Apart from
recent guidelines (n = 18), we included expired guide-
lines and guidelines under review as well (n = 4). In con-
trast to the SIGN guidelines, where expired guidelines
are automatically removed after 10 years, the German
guidelines are still available and used in clinical practice
years after their expiration (e.g. see guideline “Obsessive
compulsive disorder”, which expired 2018 and is now
“under revision”). The dementia guideline as a joint pub-
lication of DGPPN and DGN was listed twice but was
analysed as psychiatric guideline. 5 of 48 currently avail-
able SIGN guidelines were guidelines covering the do-
main of mental health. Taking the information of the
SIGN 50 developer’s handbook into consideration, these
five guidelines were methodologically comparable to
German S3-guidelines [13–17]. Please see Fig. 1 and
Table 1 for more information reading the selection
process.
Guidelines were analysed regarding the amount of rec-
ommendations, the distribution of recommendation
grades, the size of the responsible consensus groups (the
latter only applicable to German S3-guidelines). An ana-
lysis of the size of the SIGN consensus groups was not
Fig. 1 PRISMA flowchart
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performed due to the mentioned differences in the de-
velopment process and in the composition of these
groups. Since guidelines sometimes applied different
wording for grading non-evidence-based recommenda-
tions, we summarised those recommendations as “clin-
ical consensus points” (CCP). This label included the
terms “Klinischer Konsensus Punkt” (clinical consensus
point), “Expertenkonsens” (expert consensus) and “GCP”
(Good Clinical Practice). The recommendation levels A,
B and 0 were consistently used in all analysed guidelines
(also referring to Table 1 for more detailed information
on the grading system). However, the term “statement”
was used for all recommendations or declarations espe-
cially mentioned and highlighted in the guidelines with-
out having a level of evidence or grading of
recommendations. In contrast to A, B, 0 or CCP recom-
mendations statements neither involve a recommenda-
tion grade nor are they based on scientific evidence.
Nevertheless, they are based on an expert consensus and
can be seen as additional material to the recommenda-
tions. Statements were counted separately and not in-
cluded in the statistics. In some guidelines,
recommendations with two gradings like ‘A/CCP’ were
available. In such cases, both recommendation categories
were taken into account for further analyses.
Statistics
We based all analyses on the long versions of the guide-
lines. The rational for using the long version was, that we
initially expected that the long and short versions would
include the same number of recommendations. However,
as detailed below, we detected inconsistencies regarding
the number of recommendations in seven of the German
S3-guidelines. All analyses were computed using IBM
SPSS 25 (IBM, Armonk, NY, USA) with a significance
level of α = 0.05. Descriptive statistics include means,
standard deviations and maximum and minimum counts.
Mean relative frequencies of the four recommendation
grades (A, B, 0, CCP) for each of the three study groups
separately (AWMF psychiatry and psychotherapy, AWMF
neurology, SIGN mental health) were calculated based on
the individual relative frequencies of recommendation
grades within each guideline (absolute count of a given
recommendation grade (e.g. A or CCP)/absolute total
count of all recommendations). Explorative Pearson cor-
relation analyses were conducted to investigate correla-
tions between the size of the consensus group and the
relative frequencies of a given recommendation grade and
between the amount of CCP recommendations and the
total of recommendations in German S3-guidelines.
Results
In July 2019, 18 out of the 22 German guidelines were
available as a recent or updated version: 14 of them were
guidelines of psychiatry and psychotherapy and four
guidelines of neurology. The four remaining guidelines
were under revision. 5 of the available and current 48
SIGN guidelines were guidelines covering the domain of
mental health. For 14 of the German S3-guidelines a
short version was available. In 7 out of 11 [18–24] of the
guidelines of psychiatry and psychotherapy and in three
out of three neurology guidelines [25–27] we detected
discrepancies in the amount of recommendations be-
tween long and short versions. Four of the German
guidelines of psychiatry and psychotherapy and one
neurology guideline are based on the SIGN grading sys-
tem. The remaining guidelines used the OCEBM system
to grade evidence.
In the AWMF psychiatry and psychotherapy guide-
lines, 354 level A recommendations with a mean relative
frequency of 24.5% (± 19.3%; max: 76.5%, min: 0%) and
a mean absolute frequency of 20.8 (± 18.9; max: 77, min:
0) could be detected. In contrast, the AWMF guidelines
of neurology had a total of 76 level A recommendations
with a mean relative frequency of 31.6% (± 21.6%; max:
65.8%, min: 8%) and a mean absolute frequency of 15.2
(± 8.8, max: 25, min: 2). The SIGN guidelines of mental
health had a total of 46 level A recommendations with a
mean relative frequency of 31.1% (± 15%; max: 55.6%,
min: 19.6%) and a mean absolute frequency of 9.2 (± 5.8;
max: 19, min: 5).
The mean relative frequency of level B recommenda-
tions of the AWMF guidelines of psychiatry and psycho-
therapy was 18.5% (± 10.8%; max: 40.4%, min: 0%) with
a total of 320 (18.8 ± 14.3; max: 44, min: 0) level B rec-
ommendations. In the AWMF neurology guidelines, the
mean relative frequency was 29.4% (± 14.5%; max: 52%,
min: 16.7%) based on a total of 88 recommendations
(13.6 ± 6.8; max: 21, min: 6). In the SIGN guidelines, a
total of 45 level B recommendations with a mean relative
frequency of 29% (± 13.2%; max: 44.4%, min: 12.4%) and
an absolute mean frequency of 9 (± 6.5; max: 19, min: 4)
were counted.
A related pattern could be observed for level 0
recommendations, with a total of 210, a mean relative
frequency of 11.8% (± 8.7%; max: 30.8%, min: 0%) and
a mean absolute frequency of 12.4 (± 12; max: 48, min:
0) in the AWMF guidelines of psychiatry and psycho-
therapy. In the guidelines of neurology the mean rela-
tive frequency of level 0 recommendations was 22.5%
(± 15.4%, max: 40%, min: 5.6%), with a total of 54
(10.8 ± 7.8; max: 21, min: 2), while the SIGN guidelines
had a mean relative frequency of 6% (± 7.2%; max:
17.6%, min: 0%) with a total of 12 (2.4 ± 2.5; max: 6,
min: 0).
The AWMF guidelines of psychiatry and psychother-
apy had a higher relative mean frequency (45.1% ±
26.6%; max: 100%, min: 0%) of CCP recommendations
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based on a total number of 752 (44.2 ± 32.8, max: 109,
min: 0) compared to the AWMF guidelines of neurology
with a relative mean frequency of 16.5% (± 22.6%; max:
41.7%, min: 0%), based on a total of 55 (11 ± 17.5; max:
40, min: 0) of CCP recommendations. The SIGN guide-
lines had a mean relative frequency of 33.9% (± 24.3%;
max: 61.9%, min: 0%) based on a total of 92 CCP recom-
mendations (18.4 ± 24.1; max: 60, min: 0) (see Tables 2
to 3).
Only five of the 22 German S3-guidelines, 2 from
psychiatry and psychotherapy and 3 from neurology, had
exclusively level A, B and 0 recommendations and no
CCP recommendation [27–31]. However, the guideline
of functional body complaints provided only CCP rec-
ommendations [23]. In the SIGN guidelines of mental
health one out of five guidelines had no CCP recom-
mendation (guideline on non-pharmaceutical manage-
ment of depression).
Table 2 Total amount of A, B, O and CCP recommendations as well as statements and size of the consensus group for each
guideline. Year of publication and grading system are also specified for each guideline




AWMF guidelines of Psychiatry and Psychotherapy total
(year of publication/Grading system)
354 320 210 752 184 1636
Attention deficit hyperactivity disorder (2018/SIGN) 7 16 4 57 0 84 27
Schizophrenia (2019/SIGN) 32 30 9 99 8 170 38
Dementia (2016/OCEBM) 12 38 24 20 3 94 25
Obsessive compulsive disorder (2013/OCEBM) 11 8 10 34 7 63 41
Bipolar Disorder (2019/SIGN) 6 36 48 66 77 156 19
Psycho-social therapy in severe mental illness (2019/OCEBM) 10 8 0 15 11 33 42
Methamphetamine related disorders (2016/OCEBM) 77 35 17 0 7 129 17
Unipolar Depression (2015/OCEBM) 33 44 24 31 15 132 28
Screening, diagnosis and treatment of alcohol related disorders
(2016/OCEBM)
48 28 15 92 0 183 47
Screening, diagnosis and treatment of tobacco related disorders
(2015/OCEBM)
30 21 12 15 0 78 48
Treatment of anxiety disorders (2014/OCEBM) 17 7 3 34 0 61 37
Diagnosis and treatment of eating disorders (2010/OCEBM) 11 13 14 64 1 102 24
Psycho-oncological diagnostics, advising and treatment of adult
cancer patients (2014/OCEBM)
9 0 1 43 1 53 52
Post-traumatic stress disorder (2011/OCEBM) 13 2 2 0 0 17 20
Definition, pathophysiology and diagnosis of Fibromyalgia (2017/OCEBM) 20 24 10 34 48 88 35
Functional body complaints (2018/OCEBM) 0 0 0 109 109 32
Prevention of coercive interventions: Prevention and treatment
of aggressive behavior in adults (2018/OCEBM)
18 10 17 39 6 84 25
AWMF guidelines of Neurology total 76 68 54 55 40 253
Diagnosis and treatment of the cubital tunnel syndrome (2017/OCEBM) 2 13 10 0 9 25 7
Axonal injury, medical care of peripheral axonal injuries (2013/OCEBM) 15 20 21 0 16 56 10
Parkinson (2016/SIGN) 21 21 16 40 0 98 30
Lyme neuroborreliosis (2018/OCEBM) 25 8 5 0 0 38 15
Secondary prophylaxis of ischemic stroke and transient ischemic attack
(2015/OCEBM)
13 6 2 15 15 36 19
SIGN guidelines of mental health total 46 45 12 92 195
Risk reduction and management of delirium (2019/SIGN) 6 6 0 13 25
Assessment, diagnosis and interventions for autism (2016/SIGN) 19 12 0 60 97
Management of schizophrenia (2013/SIGN) 10 19 3 15 47
Management of attention deficit and hyperkinetic disorders in children
and young people (2009/SIGN)
6 4 3 4 17
Non-pharmaceutical management of depression (2010/SIGN) 5 4 0 0 9
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Exploratory correlation analyses between the num-
ber CCP recommendations and the total amount of
recommendations showed a statistically significant
positive correlation (r = 0.625, p = 0.007) for the Ger-
man guidelines of psychiatry and psychotherapy, but
no statistically significant correlation for the neur-
ology guidelines (r = 0.835, p = 0.078). For the SIGN
guidelines of mental health, the analyses showed also
a statistically significant positive correlation (r = 0.978,
p = 0.004). Analysing the German S3 guidelines of
psychiatry and neurology together, as well as all
guidelines included in this study, the number of CCP
recommendations correlated significantly with the
total number of recommendations. (r = 0.706, p <
0.001; r = 0.745, p < 0.001).
For the AWMF guidelines of psychiatry and psycho-
therapy only the exploratory correlation analyses be-
tween the size of the consensus group and the
relative frequencies of grade 0 recommendations
showed a statistically significant negative correlation
(r = − 0.516; p = 0.034). All other correlation analyses
for both AWMF groups separately, did not show sig-
nificant correlations between the relative frequency of
a given recommendation grade and the size of the
guideline group. Analysing all AWMF guidelines
(N = 22), a statistically significant negative correlation
for grades B (r = − 0.498 and p = 0.018) and 0 (r = −
0.632, p = 0.002) and a statistically positive correlation
for CCP recommendations (r = 0.591; p = 0.004) with
the size of the guideline group were detected. These
correlations indicate that in guidelines with increasing
size of the consensus groups, the number of CCP
recommendations increases as well. For B and 0
recommendations, the reverse relationship was ob-
served. For grade A recommendations, no significant
correlation was detected (r = − 0.176; p = 0.435).
Conclusion
Our study shows for the first time that the relative mean
frequency of recommendations in the German psych-
iatry and psychotherapy guidelines, which are not rooted
in strong scientific evidence amounts to 45.1%. In neur-
ology guidelines this frequency is only 16.5%. This ob-
servation of a high frequency of CCP recommendations
in the German psychiatry and psychotherapy guidelines
is even higher than in the SIGN guidelines of mental
health with a relative mean frequency of 33.9%. Inde-
pendent of the discipline, the relative mean frequency of
CCP recommendations correlates positively with the size
of the consensus group in the evaluated German guide-
lines. In general, an increasing number of recommenda-
tions correlates positively with a higher number of CCP
recommendations.
The reasons for these phenomena remain elusive, but
one could build several hypotheses to explain the high
proportion of CCP recommendations in psychiatry and
psychotherapy guidelines. First, one could assume that
for some clinically relevant questions respective clinical
trials and subsequent meta-analyses are yet lacking. In
this regard, one might argue that the responsible guide-
line groups aim to ask and try to answer such questions
that cannot be addressed ethically in clinical trials but
are of particular importance for clinical practice. Such
scenarios include e.g. suicidality, coercive treatment or
Table 3 Statistical analysis of mean, standard deviation (SD), minimum and maximum of the relative and absolute amount of
recommendations. Psychiatry refers to psychiatry and psychotherapy
N Mean [% (absolute)] SD [% (absolute)] Minimum [% (absolute)] Maximum [% (absolute)]
AWMF Psychiatry 17
A 24.5 (20.8) 19.3 (18.9) 0 (0) 76.5 (77)
B 18.5 (18.8) 10.8 (14.3) 0 (0) 40.4 (44)
0 11.8 (12.4) 8.7 (12.0) 0 (0) 30.8 (48)
CCP 45.1 (44.2) 26.6 (32.8) 0 (0) 100 (109)
AWMF Neurology 5
A 31.6 (15.2) 21.6 (8.8) 8 (2) 65.8 (25)
B 29.4 (13.6) 14.5 (6.8) 16.7 (6) 52 (21)
0 22.5 (10.8) 15.4 (7.8) 5.6 (2) 40 (21)
CCP 16.5 (11) 22.6 (17.5) 0 (0) 41.7 (40)
SIGN 5
A 31.1 (9.2) 15 (5.8) 19.6 (5) 55.6 (19)
B 29 (9) 13.2 (6.5) 12.4 (4) 44.4 (19)
0 6 (2.4) 7.2 (2.5) 0 (0) 17.6 (6)
CCP 33.9 (18.4) 24.3 (24.1) 0 (0) 61.9 (60)
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the need of supervision as part of the therapeutic
process. Being aware that we only investigated two dif-
ferent medical disciplines, one could speculate, that the
differences in the numbers of evidence- and consensus-
based guidelines between psychiatry/psychotherapy and
neurology (only five of 96 were classified as an S3-
guideline) could indicate that in neurology the respon-
sible society tries to avoid the development of such time-
and money-consuming guidelines. Concerning the SIGN
guidelines, the mean frequency of 33.9% of CCP recom-
mendations shows that the observation of a high number
of non-evidence-based recommendations in guidelines
of psychiatry and psychotherapy seems to be an inter-
national phenomenon. Based on the additional analyses
of the correlation between the total of recommendations
and CCP recommendations, the findings of Baird et al.
seem to affect only the German guidelines of psychiatry
and psychotherapy. Analysing all SIGN guidelines Baird
et al., detected a positive correlation between the in-
creasing number of recommendations and the propor-
tion of CCP recommendations. In our analyses we could
confirm this relationship showing that this is an inter-
national phenomenon.
This overall effect and the limited scientific evidence
in a magnitude of psychiatry and psychotherapy guide-
lines are critical, because such effects may support the
self-confidence and interests of expert groups [32]. The
impact of conflict of interest on guideline recommenda-
tions is evident and has been extensively investigated
[33, 34]. A relevant risk of bias can be assumed based on
our analyses of the number of recommendations in the
S3-guidelines of psychiatry and psychotherapy and the
SIGN guidelines. This conclusion cannot be generalized
for those recommendations that were based on respect-
ive scientific evidence (mainly recommendations for
pharmacological and psychotherapeutic interventions).
One could speculate, that our exploratory finding of a
positive correlation of the size of the consensus group
and the relative frequency of CCP recommendations
could support a possible relationship between financial
and non-financial (e.g. membership in specific societies,
affiliation to a specific therapeutic school, offering of
specific courses) conflicts of interest and the approval of
non-evidence-based recommendations. The greater the
size of the consensus group, the more different groups
of interest are represented. A high number of different
stakeholders may possibly lead to an influence of the
CCP recommendations by the different groups to main-
tain their own interests. However, we did not investigate
the conflict of interest statements in the included guide-
lines, but taking into account earlier findings that in all
German S3- guidelines only 76% contain a detailed dec-
laration of the conflicts of interests and in total 55% of
the participants of the guideline groups report any
conflict of interest [32], one could speculate about a re-
lationship between conflicts of interest and the amount
of non-evidence-based recommendations. However, we
could not establish this effect when both disciplines were
analysed separately.
Additionally, it appears of importance to differentiate
between “expert opinion” and “CCP” recommendation:
“Expert opinion” describes a level of evidence, not a
grade of recommendation. Even a CCP recommendation
does not automatically mean, “lack of scientific evi-
dence” nor it is only “eminence based” [35]. Though in
the grading system the level of evidence on which CCP’s
are based, is “no level of evidence”. This rather means,
there is lack of literature research or the results of the
investigated studies do not fully address the question of
the guideline and have to be adjusted. For the most
questions, studies or at least case reports exist. This
points to some kind of a scientific background, which
could be transferred to the questions of the guideline.
One could speculate, that for recommendations where
the guideline group has to transfer results, case reports
or sometimes even practical knowledge in terms of
“good clinical practice” room for interpretation is left. In
these cases, the personal view of every member of a
guideline group is more emphasized.
In this context, it may be possible that small groups of
experts and stakeholders will drive the practice of a spe-
cialty in one direction. At the same time, respective
high-quality clinical trials or meta-analyses in psychiatry
and psychotherapy beyond studies regarding efficacy and
effectiveness of pharmacological and psychotherapeutic
interventions are lacking. In our view, there seems to be
two possible options to address the outlined issue of
conflicts of interest: The first option would be, not to
provide any recommendations for clinical scenarios
where no evidence is available yet. However and as dis-
cussed before, treatment guidelines without any non-
evidence-based recommendations while having a higher
methodological standard, would potentially ignore many
clinically important scenarios and questions. The latter
may result in a guideline that might be less useful in
clinical practice due to the lack of importance and ap-
plicability for a variety of questions. Moreover, one
should bear in mind that the absence of evidence does
not equal the evidence of absence. For example, until
today no randomised-controlled trial has been
conducted to show that using a parachute is more effect-
ive to save lives than not using parachutes [36]. The sec-
ond option would be to accept the aforementioned
potential risk of bias and include recommendations
based on expert consensus, as these can address clinic-
ally meaningful questions and scenarios. Obviously, such
recommendations can be useful where clinical trials and
meta-analyses are missing to facilitate the clinical
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decision-making process and to contextualise the
decision-making of individuals with the views of experts.
By contrast, a high number of such recommendations
can foster uncertainty in the clinical decision-making
process [37] due to the aforementioned increase in the
risk of bias. Situations where recommendations based on
expert consensus are necessary and helpful are not rare,
neither in psychiatry and psychotherapy nor in other
medical disciplines. Such areas are e.g. situations of
ultra-treatment resistance, areas that are difficult to
study (e.g. suicidality, coercive treatment), the manage-
ment of rare side-effects, the combination treatment
with different pharmacological compounds or the evalu-
ation of long-term effectiveness and tolerability. In these
cases, standard operating procedures (SOPs) on how to
develop and approve non-evidence-based recommenda-
tions should be implemented for the guideline develop-
ing process. Such SOPs that provide a process for the
development of CCP recommendations are missing in
the AWMF and SIGN guideline developer’s handbooks.
These SOPs could e.g. describe exactly the development
and composition of each CCP recommendation and in-
clude the total number of CCP recommendations (e.g.
not more than 15% or 20% of all recommendations) to
force guideline developers to limit these recommenda-
tions to a minimal clinically relevant amount or the need
to involve independent international experts in the
process (e.g. using the Delphi method).
Another aspect is that the composition of the guideline-
developing group could influence the amount of CCP rec-
ommendations. Following Baird and Lawrence [11], a high
amount of recommendations based on expert opinions could
be seen as a reflection how professional groups deal with un-
certainty [11]. Moreover, they speculate [11] that expert
groups may view their opinion as clinical experts being more
authoritative than scientific evidence [38]. The more experts
from different fields and interest groups are involved, the
more differing opinions might exist and the more uncer-
tainty might arise. Thus, the important development towards
multi-professional guideline groups, involving stakeholders,
relatives and other involved persons may foster the inflation
of non-evidence-based recommendations. This may be espe-
cially true, as in many of the German S3-guidelines in psych-
iatry and psychotherapy involved groups the same persons
are responsible for different guidelines (e.g. being a delegate
for guidelines in general). Moreover, in contrast to e.g. SIGN,
AWMF gives no restriction concerning the maximum size
of the guideline group. Our general finding that the more
groups are involved in a guideline, the more non-evidence-
based recommendations are included supports to the de-
scribed dilemma. Potential solutions could be to limit the
size of the guideline groups, to limit the possibility for one
person to participate in several guideline-development pro-
cesses, to define standards of the qualifications of the
involved person and to develop between-guideline standards
for the here raised important issues.
Our analysis showed also that in some guidelines the
number of recommendations differs between the short
and the long version. Furthermore, in some guidelines
the grading differed between both versions (e.g. in the
guideline of Obsessive Compulsive Disorder recommen-
dation number 4–10 is graded as CCP in the short ver-
sion and as a statement in the long version [19]). Such
findings question whether short versions of guidelines
are necessary and might motivate guideline developers
to pay attention to such discrepancies.
As a limitation, we only included guidelines of
neurology as control group from Germany, which
consisted only of five S3-guidelines. By comparison,
analyses such as the one presented by Baird and
Lawrence for the SIGN guidelines are not available
for Germany. Thus, we cannot derive statements with
respect to other medical disciplines. Moreover, with a
total of 96 the number of neurology guidelines is very
high and we assume that the only available five S3
guidelines may have had a stricter methodology
approach than the remaining 91 resulting in an over-
estimation of the frequency of evidence-based recom-
mendations. Secondly, our correlative findings are
only significant when both disciplines are analysed.
Another limitation is, that we solely analysed the
current published SIGN guidelines of mental health
for an international comparison, which consisted also
only in five guidelines. Moreover, four of the German
guidelines were out of date, while we used only
current SIGN guidelines. This must be considered
also as a potential limitation.
In summary, we were able to show a high frequency of
non-evidence-based recommendations in S3-guidelines
of psychiatry and psychotherapy. Furthermore, we could
demonstrate that the size of the involved group seems to
affect and promote the development of such recommen-
dations. As guidelines should be practical tools to
simplify the clinical decision-making processes based on
scientific evidence in times of multiple treatment op-
tions, our findings support a view that new strategies to
deal with clinically relevant questions where no evidence
is available are needed. For reasons of practical applic-
ability, guideline developers in general should be careful
about the included amount of recommendations and the
scientific evidence on which the recommendations are
based.
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